[Breast cancer in men: about 6 cases]

Breast cancer in adult man treated in a rural hospital: A case report

INTRODUCTION AND IMPORTANCE

Breast cancer in a male patient is an uncommon condition known by the general public yet of the same concern as in a female patient.

CASE PRESENTATION

A 64-year-old male with a 25 years history of a progressive swelling in the right breast, underwent an ultrasound guided biopsy which revealed a mucinous carcinoma of grade SBR I, right mastectomy with lymph-node dissection were done. His postoperative period was uneventful and patient was a live on 7th post-operative day. Chemotherapy and radiotherapy are being considered.

CLINICAL DISCUSSION

Being rare, breast cancer in males should be fully evaluated and investigated to avoid the associated morbidity and mortality.

CONCLUSION

Male breast cancer though rare exists and its management follows the same principles as in women. There is a need to do genetic tests to identify patients at risk and guide preventive measures in case of any breast swelling despite the gender.

Male Breast Cancer in Togo: Imaging and Clinicopathological Findings

Background

Breast cancer in men is a rare condition, often diagnosed late. The purpose of this study was to describe its epidemiological, histopathological, and radiographic aspects in Togo.

Materials and Methods

This was a descriptive retrospective study on cases of breast cancer in humans diagnosed histologically at the Laboratory of Anatomy Pathological and Imagery of the University Hospital in Lomé, over a period of 25 years (1995 to 2019). The parameters studied were epidemiological, anatomopathological, and imaging.

Results

Eighty-two (82) cases were diagnosed, an annual frequency of 3.28 cases. The mean age was 45 ± 2.5 years; the range was 27-63 years. The family history of 47 patients (57.32%) was known. Carcinomas represented the predominant histological group with predominantly nonspecific invasive carcinoma (87.5%). These cancers were diagnosed at late stages (75.71% grade II). They were mainly of luminal B profile (38.75%) and associated with mutations of the BRCA2 and BRCA1 genes in 14.63% of the cases. The lesions were classified ACR 5 in 61.5% (11/18). Two cases of breast angiosarcoma were diagnosed by the identification of CD31 markers and factor VIII in immunohistochemistry. Hormone therapy such as tamoxifen was prescribed in all luminal patients (43 patients). Radiotherapy was administered to 15 patients (18.3%), with acute toxicity in 20% of the cases. After a median follow-up of 36 months, the evolution was complete remission in 27 patients (32.93%).

Conclusion

Breast cancer in men is rare, often diagnosed late with a poor prognosis.

Male breast cancer: diagnosis stages, treatment and survival in a country with limited resources (Burkina Faso)

BACKGROUND

Male breast cancer is a rare and less known disease. Therapeutic modalities affect survival. In Burkina Faso, male breast cancers are diagnosed in everyday practice, but the prognosis at short-, middle-, and long-term remains unknown. The objective of this study is to study the diagnosis stages, therapeutic modalities, and 5-year survival in male breast cancer at the General Surgery Unit of Yalgado Ouedraogo University Hospital from 1990 to 2009.

METHODS

A cohort longitudinal study concerning cases of breast cancer diagnosed in man. Survival was assessed using the Kaplan-Meier method and survival curves were compared through the LogRank test.

RESULTS

Fifty-one cases of male breast cancer were followed-up, i.e., 2.6% of all breast cancers. Stages III and IV represented 88% of cases. Eleven patients (21.6%) were at metastatic stage. Patients were operated in 60.8% of cases. The surgery included axillary dissection in 25 (80.6%) out of 31 cases. Lumpectomy was performed on 6.5% of patients (2 cases). Fifteen (29.4%) and 11 (21.6%) patients underwent chemotherapy and hormonal therapy, respectively. The FAC protocol was mostly used. Radiation therapy was possible in two cases. The median deadline for follow-up was 14.8 months. A local recurrence was noticed in 3.2% of cases. The overall 5-year survival rate was 49.9%. The median survival was over 5 years for stages I and II. It was 54 down to 36 months for stages III and IV.

CONCLUSION

Diagnosis is late. The lack of immunohistochemistry makes it difficult to define the proportion of their hormonal dependence. Surgery is the basic treatment. Five-year survival is slow and the median survival depends on the diagnosis stage. It can be improved through awareness-raising campaigns and the conduct of individual screening.

[Breast cancer in men: about 40 cases and literature review]

Breast cancer in men is rare, accounting for approximately 1% of all breast cancers and less than 1% of all neoplasias in men. This study aimed to highlight the clinical histological, prognostic and therapeutic features of this rare tumor in order to contribute to improve the management of these patients. We conducted retrospective study of 40 patients whose data were collected at the Mohammed VI Center for Cancers Treatment in Casablanca from January 2000 to December 2012. The average age was 62 years, the mean consultation time was 12 months, self-exam of a peri-areolar nodul was the main reason for consultation in 90% of cases. Infiltrating ductal carcinoma was the predominant histological type in 90% of cases. Multimodal treatment was based on mastectomy followed by adjuvant therapy including chemotherapy, radiation therapy and/or hormonal therapy, depending on tumor stage and its histological features. The mean follow-up time was 38 months, patient's evolution was characterized by complete remission in 16 patients (40%), local recurrence in 3 patients (7.5%) and metastatic recurrence in 5 patients (12.5%). Metastases mainly occurred in the bones (62%), followed by the lungs and the liver. 10 patients (25%) died. Breast cancer in men is similar to breast cancer in women. However it has its own peculiarities, hence the importance of conducting broader prospective randomised studies in order to improve the treatment and the prognosis of this disease with a high psychosocial impact.